Reviews/Alzheimers Disease Treatment/Cholinesterase inhibitors give symptomatic benefit
Symptomatic · AD-SYM-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Several placebo-controlled trials tested approved cholinesterase inhibitors in people with Alzheimer's disease and measured thinking and memory on standard scales. In mild-to-moderate disease, galantamine improved cognitive scores versus dummy treatment [24], and in moderate-to-severe disease continued donepezil kept cognition higher than stopping it [1], as did donepezil in severe disease [25]. A very large real-world registry of over 17,000 patients found a small cognitive advantage that lasted over years [28]. The improvements are small, and the panel noted the claim's own wording ('modest') fits them well. The review also flags that the registry study cannot prove cause by itself, that a couple of supportive items are off-population or a single case, and that the strongest review-type evidence was set aside by the panel's study-type rules.
Three independent placebo-controlled randomised trials across two molecules and the full severity range show statistically significant cognitive benefit on validated instruments: galantamine improved ADAS-cog by 3.9 and 3.8 points at six months [24]; continued donepezil gave an SMMSE advantage of 1.9 points (95% CI 1.3 to 2.5) exceeding its stated 1.4-point minimum clinically important difference [1]; and donepezil in severe disease gave an SIB least-squares mean difference of 5.7 (95% CI 1.5 to 9.8) [25]. A propensity-matched registry cohort of 17,478 patients found higher MMSE at each visit (0.13 points per year, 95% CI 0.06 to 0.20) and described the effect as modest but persistent [28]. The magnitudes are small and align with the claim's 'modest' wording. The contested point: The division is over how firmly the benefit is established rather than its direction: the large cohort [28] is observational and open to confounding-by-indication, and the strongest confirmatory syntheses were removed by the mandatory study-type filter, leaving the verdict resting on three RCTs plus one cohort. There is also debate over clinical meaningfulness of small effects, though [1] exceeds its stated minimum clinically important difference.
All 38 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alzheimers Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The cohort evidence [28] is observational and vulnerable to confounding-by-indication (fitter patients are more likely treated), so it corroborates but cannot by itself establish a causal cognitive benefit.
The highest-quality syntheses (Cochrane meta-analysis [35]; efficacy review [27]) were removed by the mandatory study-type filter, so the corpus cannot here exploit its strongest corroboration; the verdict leans on three RCTs plus one cohort.
Where it remains uncertain. The supporting cohort [28] is observational and open to confounding-by-indication, and the strongest syntheses were excluded by the study-type filter, so corroboration rests on primaries alone.
Aleatory
The severe-AD trial [25] has 248 patients and a wide SIB confidence interval (1.5 to 9.8), so the point estimate carries sampling variability
Epistemic
The highest-quality meta-analysis [35] and efficacy review [27] were removed by the study-type filter, so the corpus cannot here use its strongest corroboration
Inferential
The cohort [28] is observational; fitter patients being more likely treated could inflate the apparent cognitive signal
The load-bearing papers from a corpus of 38, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT evidence of a cognitive benefit exceeding the minimum clinically important difference, consistent with a modest effect.
“Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5)”
Panel auditInternal validity: high · scope of inference: Patients with moderate-to-severe AD already on donepezil for at least 3 months.Key limitations: moderate-to-severe only · continuation/withdrawal design not initiation
Independent RCT of galantamine confirming significant, modest cognitive improvement in mild-moderate AD.
“the treatment effects were 3.9 points (lower dose) and 3.8 points (higher dose) on the ADAS-cog/11 scale at month 6 (p < 0.001 in both cases)”
Panel auditInternal validity: high · scope of inference: Mild-to-moderate AD over 6 months.Key limitations: open-label extension uncontrolled · mild-to-moderate only
Extends the cognitive benefit to severe AD, broadening the severity range covered.
“Patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores at 6 months after initiation of treatment compared with baseline than did controls (least squares [LS] mean difference, 5.7, 95% CI 1.5-9.8; p=0.008”
Panel auditInternal validity: high · scope of inference: Severe AD in nursing-home residents over 6 months.Key limitations: severe-stage population · more adverse-event discontinuations on donepezil · LOCF imputation
Single uncontrolled case with donepezil given alongside other therapies, so no attributable direction.
Panel auditInternal validity: low · scope of inference: One patient with logopenic-variant AD and mixed vascular pathology.Key limitations: n=1 · no control · co-interventions
4 of 38 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Convergent, independent primary RCT and cohort evidence directly supports a well-hedged claim whose asserted magnitude ('modest') matches the observed effect sizes.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Causal confirmation beyond confounding. The durable effect rests on an observational cohort [28] open to confounding-by-indication, so causation is corroborated but not anchored The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-duration RCT or target-trial-emulation design measuring sustained cognitive trajectory
Open question: Does rivastigmine produce a comparable modest cognitive benefit on validated scales in AD? Why it is still open: No included primary in this corpus isolates rivastigmine, so the class claim is supported only for donepezil and galantamine
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19